Compare HOLX & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOLX | SNN |
|---|---|---|
| Founded | 1985 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical Electronics | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.6B | 14.0B |
| IPO Year | 1990 | 1999 |
| Metric | HOLX | SNN |
|---|---|---|
| Price | $74.98 | $33.44 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 15 | 4 |
| Target Price | ★ $79.64 | $32.83 |
| AVG Volume (30 Days) | ★ 3.0M | 476.9K |
| Earning Date | 11-03-2025 | 03-02-2026 |
| Dividend Yield | N/A | ★ 2.19% |
| EPS Growth | N/A | ★ 59.91 |
| EPS | ★ 2.49 | 0.56 |
| Revenue | $4,100,500,000.00 | ★ $5,944,000,000.00 |
| Revenue This Year | $6.69 | $7.78 |
| Revenue Next Year | $5.74 | $5.13 |
| P/E Ratio | $30.11 | ★ $29.10 |
| Revenue Growth | 1.74 | ★ 5.35 |
| 52 Week Low | $51.90 | $23.69 |
| 52 Week High | $80.31 | $38.79 |
| Indicator | HOLX | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 67.93 | 48.01 |
| Support Level | $74.55 | $32.68 |
| Resistance Level | $75.12 | $33.56 |
| Average True Range (ATR) | 0.28 | 0.41 |
| MACD | -0.14 | 0.14 |
| Stochastic Oscillator | 78.92 | 78.51 |
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.